GAITHERSBURG, Md., November 5, 2025 — Leads & Copy — Altimmune, Inc. (Nasdaq: ALT) will participate in investor conferences. Management will be available for one-on-one meetings at the Stifel 2025 Healthcare Conference on November 12, 2025, and the Jefferies Global Healthcare Conference on November 20, 2025.
Sessions will be webcast and accessible on Altimmune’s website.
Altimmune develops peptide-based therapeutics for liver and cardiometabolic diseases. The company’s lead product is pemvidutide for MASH, AUD, and ALD.
Investor Contact: Lee Roth, Burns McClellan, Phone: 646-382-3403, lroth@burnsmc.com
Media Contact: Elliot Fox, Real Chemistry, efox@realchemistry.com
This press release was published by a CLEAR® Verified individual.
Source: Altimmune
